Latest Regulatory News

Telix Pharmaceuticals has initiated a US$550 million convertible bonds offering to refinance existing 2029 bonds and support general corporate purposes, securing low-cost, non-dilutive financing with a conversion premium above current share price.

Rhythm Biosciences has clarified inconsistencies in its disclosures around termination events in its underwriting agreement for RHYO options, following an ASX query. The company acknowledged an incomplete initial summary and administrative oversights but confirmed the agreement remains in full effect.

Tarrina Resources (ASX: TR8) has addressed ASX’s query on recent share price movement, confirming it has dispatched soil and drill core samples for laboratory testing with results expected by late April. The company maintains strict confidentiality protocols and affirms compliance with continuous disclosure rules.

Cuscal Limited is set to acquire New Zealand payments provider Paymark for A$27 million, funded by a fully underwritten A$30 million institutional placement and a non-underwritten A$3 million share purchase plan. The deal, expected to complete by June 2026, will add scale and geographic diversification while being accretive to earnings in FY27.

Winton Land has gained conditional fast-track approval for its Ayrburn Screen Hub, a comprehensive film production and accommodation facility near Arrowtown, promising regional economic and environmental benefits.

Kjerulf David Hastings Ainsworth has taken a sharper stance in his bid for Ainsworth Game Technology, opposing Novomatic’s constitutional takeover protections while nominating a former CEO for the board and pressing for a dividend policy amendment.

Holista Colltech’s shares remain suspended on the ASX following a trading halt linked to ongoing legal issues with ProImmune Company LLC, with no resolution in sight.

The Takeovers Panel has temporarily stayed its previous orders against Humm Group Limited following a review application by Mr Andrew Abercrombie. The interim measure preserves the status quo while the review is underway, delaying enforcement of the initial rulings.

Entropy Neurodynamics has dosed its third patient with TRP-8803 in a Binge Eating Disorder trial, achieving a full and controlled psychedelic response that underscores the drug’s potential for precise therapeutic delivery.

Zeotech Limited has made significant progress on its Toondoon Kaolin Project, securing critical environmental approvals, advancing mine planning, and preparing for an initial kaolin shipment amid rising contractor cost pressures.

PainChek has secured a landmark agreement with Sabra Health Care REIT to deploy its AI-powered pain assessment across up to 20,000 beds in North America, marking a pivotal step in its US expansion.

Resolution Minerals has produced a high-purity antimony trioxide intermediate from its Antimony Ridge project using conventional pyrometallurgy, while hydrometallurgical tests progress. The project benefits from US FAST-41 permitting, aiming to establish a local processing hub for critical metals in Idaho.